RG
CRSP icon

Retirement Group’s CRISPR Therapeutics CRSP Stock Holding History

Retirement Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$13.6K Sell
200
-323
-62% -$23.1K ﹤0.01% 413
2023
Q4 		$32.7K Buy
+523
New +$28.9K 0.01% 270
2022
Q4 		– Sell
-323
Closed -$21K – 652
2022
Q3 		$21K Buy
+323
New +$23.4K 0.02% 172
2021
Q3 		– Sell
-323
Closed -$52K – 640
2021
Q2 		$52K Sell
323
-536
-62% -$65.2K 0.03% 234
2021
Q1 		$105K Buy
859
+536
+166% +$80.9K 0.05% 178
2020
Q4 		$49K Hold
323
– – 0.02% 261
2020
Q3 		$27K Buy
+323
New +$28.7K 0.02% 298

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Retirement Group's CRSP Position: Q1 2024 in Review

Retirement Group reduced its CRISPR Therapeutics (CRSP) stake by 62% in Q1 2024, selling an estimated $23.1K and leaving 200 shares worth $13.6K. The position accounts for ﹤0.01% of the portfolio, ranked #413.

Retirement Group first reported a position in CRSP in Q3 2020 and has held it in 7 quarters since. The position peaked at $105K in Q1 2021. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • Retirement Group held 200 shares of CRISPR Therapeutics worth $13.6K as of Q1 2024.
  • Retirement Group sold 323 CRISPR Therapeutics shares in Q1 2024, an estimated $23.1K.
  • CRISPR Therapeutics made up ﹤0.01% of Retirement Group's portfolio in Q1 2024, its #413 holding.
  • Retirement Group first reported a position in CRISPR Therapeutics in Q3 2020 and has held it in 7 quarters since.
  • Retirement Group's CRISPR Therapeutics position peaked at $105K in Q1 2021.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Retirement Group's 13F filing for Q1 2024, filed 30 Apr 2024.